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Abstract  
Clusterin (CLU), also known as apolipoprotein J, is a widely expressed, heterodimeric, glycoprotein, important 
in tumourigenesis, apoptosis, and immunoregulation. In humans, clusterin expression has been associated 
with anaplastic large cell and Hodgkin's lymphoma. In this study, serum clusterin levels in dogs with 
multicentric lymphoma (MLSA) were compared to healthy control dogs, using both western blot and ELISA.  
Western blot confirmed the presence of clusterin in dog sera at the predicted molecular weight and the 
relative levels detected correlated with the levels detected by ELISA. Clusterin level analysis by ELISA found 
treatment naïve dogs with MLSA had a significantly (p<0.001) lower serum clusterin level compared to healthy 
controls. However, there was no significant difference between MLSA dogs prior to treatment and in complete 
remission. The wide variation in serum CLU levels may limit its potential as a single candidate biomarker for 
MLSA, although any prognostic predictive value of serum CLU concentrations has yet to be assessed.  
Keywords: Biomarkers, CLU protein, Clusterin, Dogs, Lymphoma. 
 
Introduction 
Lymphoma is a malignant neoplasm which arises from a clonal proliferation of lymphoreticular cells.1 It is the 
most common canine haematopoietic neoplasm,1,2 accounting for 7-24% of all canine malignancies.3–5 Multiple 
blood6–12 and tissue13,14 biomarkers have been investigated regarding potential prognostic or diagnostic use in 
canine lymphoma, however no single marker has proved more valuable than established parameters e.g. 
stage, substage, immunophenotype.  
 
Based on observations from human studies, one potential candidate biomarker for haematopoietic mediated 
disorders is the protein clusterin.  Initially identified in the fluid of ram rete testes, the clusterin (CLU) protein 
was found to elicit aggregation, or clustering, of a variety of different cells.15 The CLU gene is unique in the 
genome and well conserved, with the structure of the clusterin protein showing little variation between 
species.16–18 The CLU gene codes for at least three different protein forms; nuclear, cytoplasmic and secretory, 
each with different biological functions.19,20 Secretory CLU, formed in the Golgi apparatus, enters the 
extracellular compartment as a glycosylated protein.21  This extracellular form of the CLU protein, also known 
as apolipoprotein J, is a heterodimeric, glycoprotein composed of an  and  subunit20,22 comigrating at 
approximately 37 kDa by SDS-PAGE. 
 
From the extracellular compartment CLU binds to a number of serum proteins including albumin23 and 
complement factors. CLU is heavily glycosylated, a feature which can affect both the nature of the protein 
itself, and its binding properties. Expressed in virtually every body tissue and fluid,21,24–27 CLU has been linked 
to multiple biological processes important for tumourigenesis; including apoptosis, tissue remodelling, 
membrane recycling, cell cycle regulation and immune system regulation.18,24,27–29 Regulated by cytokines and 
growth factors, increased CLU gene expression is also seen in response to physiological stress.24,25,28  
Dysregulation of CLU, in both tissue and serum, has been associated with various human malignancies,20,28,30,31 
including prostatic20,32 and mammary20,33–35 carcinoma, oesophageal squamous cell carcinoma,36 
hepatocellular carcinoma37 and colorectal neoplasia,29,38 with CLU implicated both as a tumour suppressor39,40 
and modifier of tumour promotion.39 These studies suggest that dysregulation of CLU expression, whether 
upregulated or downregulated, may have a key role in tumourigenesis.  
 
Cytoplasmic expression of CLU has been positively identified, via immunohistochemistry (IHC), in cases of 
anaplastic large cell lymphoma.31,41–43 Serum CLU expression was also upregulated in a subset of patients 
following treatment for Hodgkin's lymphoma. 
 
Little has been reported regarding clusterin expression in canine malignancies. However, a previous study of 
the canine proteome, identified clusterin expression in the serum of a dog with high grade multicentric 
lymphoma, and the absence of clusterin expression in serum from two healthy controls.44 The objective of this 
study was to determine whether serum clusterin expression differed significantly between a cohort of dogs 
with untreated high grade multicentric lymphosarcoma (MLSA), those in complete remission (CR) after 
chemotherapy, and a healthy control population.  
 
Materials and Methods 
Sample selection  
Archived serum samples were searched to identify canine patients, who presented to the University of 
Glasgow Small Animal Hospital between 2013 and 2018, with a confirmed cytological and/or histopathological 
diagnosis of high grade MLSA. Retrospective analysis of the medical records was performed, to obtain 
information pertaining to signalment, WHO stage (I-V) and substage (a = no clinical signs, b = clinical signs),1,45 
immunophenotype/genotype and clonality (from immunohistochemistry, flow cytometry or PARR analysis), 
treatment and response. Due to the retrospective nature, staging was not standardised, and stage migration 
could not be excluded.  
 
After identifying suitable patients, MLSA samples were further categorised as either; 1) pre-treatment, taken 
at time of diagnosis, prior to any corticosteroid or chemotherapy treatment, or 2) in complete remission (CR), 
at week 4-6 of a (CHOP-based) chemotherapy protocol. Remission was determined, by a qualified veterinary 
surgeon experienced in veterinary oncology, using RECIST46 guidelines, by physical examination and lymph 
node palpation. 
 
Exclusion criteria included severely haemolysed or lipaemic samples, concurrent infectious or systemic 
inflammatory disease and prior treatment. Samples from dogs who failed to achieve complete remission, and 
those who received alternative chemotherapy protocols were excluded from the CR sample pool.  
 
Control serum samples were obtained from the Canine Pet Blood Bank, when collected for screening and 
monitoring purposes, at the time of blood donation. These were stored at -20 °C prior to transport and 
transported frozen to Glasgow.   
 
The study was performed with full ethical approval from the Ethics and Welfare committee at the University of 
Glasgow, with owner consent obtained for the retention of spare serum. All serum samples were surplus 
blood, from samples collected for diagnostic and treatment purposes. Clotted serum samples were centrifuged 
at 9000rpm for 3 minutes, serum was extracted and stored frozen. All serum samples were stored frozen, at -
20 °C prior to transfer for storage at −80 °C, for analysis at a later date. 
 
Sample groups   
All samples were selected, from the previously identified pool of suitable samples and controls, to generate 
three distinct sample groups. When creating these sample groups, preference was given to samples with 
shorter storage history, samples with larger sample volume, and samples with higher burden of disease (i.e. 
Stage III or above, as per the WHO staging system).  
 
Sample group one consisted of 3 cohorts; dogs diagnosed with MLSA, pre-treatment (A, n=12), unrelated dogs 
with MLSA, in CR (B, n=12) and healthy control dogs (C, n=12), (Table 1). 
Sample group two consisted of 2 cohorts; dogs diagnosed with MLSA, pre-treatment (n=18), and in CR (n=18), 
i.e. paired samples from the same individuals, (Table 2). 
Sample group three consisted of 2 cohorts; dogs diagnosed with MLSA, pre-treatment (n=18) and healthy 
control dogs (n=18), (Table 3). Samples for group three were intentionally selected to form age matched 
cohorts. 
 
Assessment of serum Clusterin level 
Two methods were employed to assess the level of serum clusterin: western blot was performed using a 
commercial anti-human antibody, predicted to have cross species reactivity with dog at 93%, and previously 
validated47,48 in the dog. Enzyme-linked immunosorbent assay (ELISA), was performed using a commercial 
(BioVendor Ltd) kit, previously validated using canine serum. 
 
Western blot analysis  
The presence of CLU in individual serum samples was initially evaluated via western blot analysis, as previously 
described.47,48 In brief, protein concentrations of the serum samples were determined using a bicinchoninic 
acid (BCA) protein assay system (Thermo Life Science Ltd, UK); 10ug aliquots of each sample were separated 
by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS – PAGE) using Criterion 26 well gels 
(BioRad Ltd, UK), and then transferred to nitrocellulose membranes using the iBlot system (Invitrogen, Thermo 
Fisher, UK). Samples from diseased and control dogs were loaded in alternate wells, with protein molecular 
weight standards (BioRad Ltd, UK) run in the first and last well of each gel.   
 
Following transfer, the membranes were blocked in 5% semi skimmed, milk solution with Tris- buffered saline 
containing 0.5% Tween 20 (T-TBS) and incubated overnight, at 4°C, with a goat primary antibody against CLU 
(Antibody 104652, Abcam Ltd, UK), diluted 1:20,000. Membranes were then incubated with a horseradish 
peroxidase (HRP) conjugated secondary antibody (Abcam Ltd, UK), diluted to 1:10,000, at room temperature. 
Finally, an enhanced chemiluminescence reagent (Pierce ECL, Thermo Fisher, UK), allowed detection of the 
protein bands, with visualisation via radiographic film. Protein band density was quantified using Image-J 
software.49  
Three separate western blots were performed to compare the three cohorts in sample group one. Each 
individual cohort was directly compared to the others, via separate western blot analysis. Comparison of 
protein density between separate blots (i.e. inter-blot comparison) was not performed due to the inherent 
difficulties with variations in signal intensity between blots.  
 
ELISA 
CLU concentrations were measured using a sandwich enzyme immunoassay (BioVendor Ltd, UK) for 
quantitative measurement of canine clusterin.  This assay was previously validated, by BioVendor, to have low 
within‐run imprecision, with an intra‐assay coefficient of variance (n = 8) of 4.3%, and an acceptable between‐
run comparability, with inter‐assay coefficients of variance (n = 8) of 6.2%.  A normal canine serum CLU 
concentration range has not yet been established.   
Serum samples were diluted 1:2500 with dilution buffer [to facilitate the ELISA]. Each plate was loaded with 
samples, controls and protein standards in duplicate. The ELISA was run, as per manufacturer guidelines, using 
dilution and wash solutions provided. Following cessation of the colour change reaction, optical density of the 
samples was determined, using a microplate reader. A standard curve was generated, using results from the 
protein standards, allowing evaluation of sample clusterin concentrations.  
 
Statistical Analysis 
All analyses were performed using GraphPad Prism, version 5 for Windows (GraphPad Software, San Diego, 
California, USA) with statistical significance set at p ≤ 0.05. The serum clusterin concentrations were analysed 
using parametric and non-parametric testing, depending on normality of data distribution, with student t- test, 
Mann–Whitney U test, Kruskal-Wallis, ANOVA and Wilcoxon signed-rank tests. Group characteristics were 
compared using Mann–Whitney U test, ANOVA, Chi squared and Fisher’s exact tests.  
 
Results  
Antibody specificity was confirmed by western blot analysis prior to further investigations. Blots were 
incubated with and without the primary goat antibody against CLU (Antibody 104652, Abcam Ltd, UK) and the 
CLU protein band, visible at approximately 37kDa, was only identified following incubation with the primary 
antibody (Figure 1). This was consistent with the secreted form of CLU, which is processed to generate two 
subunits, at approximately 37kDa.27,50,51 
 
Sample group one (unrelated samples) 
Serum CLU concentrations were initially compared in 36 dogs by western blot analysis. Dogs were divided into 
3 cohorts; those diagnosed with MLSA pre-treatment (n=12), unrelated dogs with MLSA in CR (n=12) and 
healthy control dogs (n=12).  
 
Signalment of the dogs with untreated and treated MLSA was similar (Table 1). Median age was not 
significantly different between pre-treated (8 years) and CR (7.5 years) cohorts and both pre-treatment (n=9) 
and CR (n=7) were predominantly male. Healthy control dogs were also predominantly male (n=7) and there 
was no significant difference in sex or neuter status between all 3 cohorts (Chi-squared p>0.05). The median 
age (4 years) of the controls, however, was significantly younger than both MLSA cohorts (ANOVA, p<0.05).  
Stage of disease at initial presentation was higher in the pre-treatment samples, with significantly more stage 
V disease in comparison to those in CR (Fisher’s exact, p<0.01).  There was no significant difference in substage 
between the two MLSA cohorts. Of the dogs for which immunophenotype was known there was no significant 
difference; the pre-treatment cohort had seven B-cell lymphoma and one T cell lymphoma, compared to ten 
B-cell lymphoma for those in CR (Fisher’s exact, p>0.05). 
 
Serum samples from each cohort (Control vs MLSA, Control vs CR and MLSA vs CR) were compared across 
three western blots (Figure 2). Intra-blot comparison of protein band density suggested a trend for a lower 
CLU level in dogs with MLSA in comparison to controls, however there was no statistically significant difference 
between the three cohorts (p>0.05, student’s t-test, Figure 3).  
Measurement of serum CLU in the same 36 samples using a previously validated ELISA assay showed that 
median serum CLU concentration in dogs prior to treatment was 53.75ug/ml (range 15.9 – 101.1), compared 
to dogs in remission 67.0ug/ml (49.3-116.8), and 93.60ug/l (70.1- 120.1) in healthy controls.  
 
The median serum CLU concentrations differed significantly between the three groups, (Kruskal-Wallis p<0.01, 
Figure 4) and when individual groups were compared serum CLU was significantly lower (p<0.05) in MLSA than 
controls. There was no significant difference however, in serum CLU levels in those dogs with MLSA, prior to 
treatment and in remission.   
 
Sample Group Two (paired samples) 
To make allowance for individual variation the group size was expanded and  serum CLU concentrations were 
compared in a further 18 dogs. Paired samples were assessed from the same dog, at time of diagnosis (pre-
treatment) and again in CR. Signalment and MLSA phenotype were similar to that of the previously assessed 
samples (Table 2).  
 
Median serum CLU concentration of samples from dogs prior to treatment [50.36ug/ml, range 36.08 –118.1] 
was not significantly different from median serum CLU at the time of CR [51.33ug/ml, range 33.98 – 141.1], 
(Wilcoxon signed-rank test, p>0.05, Figure 5). Subjective assessment of the data identified no consistent 
trends in serum CLU concentration within individuals; 7/18 (38.9%) dogs had increased clusterin 
concentrations, while 7/18 (38.9%) decreased and 4/18 (22.2%) remained relatively static in remission.  
 
Sample Group Three (age matched samples) 
In the initial sample groups, there was a significant difference in age between dogs with MLSA and controls. To 
eliminate the bias of age on our results, an age matched sample and new control population were compared. 
Eighteen pre-treatment MLSA dogs (median age 6 years) were compared to 18 healthy controls (median age 5 
years). The age, sex and neuter status were not significantly different between the two groups (Table 3).  
The median serum clusterin concentration in pre-treatment MLSA dogs [58.34ug/ml, range 30.48 – 137.4] was 
significantly lower than healthy controls [98.93ug/ml, range 73.18 – 141.0]. (Mann Whitney U, p<0.001, Figure 
6).  
 
Discussion 
While the exact function of CLU is not precisely known, it is generally accepted that CLU acts as an extracellular 
chaperone protein,18 with functions similar to that of the small heat-shock proteins.52–54 CLU expression 
increases in response to cellular stress,16,52–54 acting to stabilise and correct protein folding, or facilitate 
degradation of misfolded proteins and assist in the clearance of these proteins from extracellular spaces. 
18,23,39,52–54 The chaperone function of secretory CLU is widely described, protecting cells from physical stress, 
neutralizing insult and facilitating clearance and disposal of toxic molecules.18,53  Therefore, changes in the 
regulation of expression and steady state levels of clusterin may occur as a consequence of a postulated role in 
tumourigenesis. Indeed, some studies in humans have suggested that down regulation and subsequent loss of 
CLU’s chaperone function could play a role in tumourigenesis. 20,28,55,56 
 
In 2013, Atherton et al characterised the serum proteome of dogs with lymphoma, via serum protein 
electrophoresis and mass spectrometry. In this study multiple proteins, which were not identified in healthy 
dogs, were identified in dogs with lymphoma, although sample sizes were very small. In one dog with 
lymphoma, a clusterin precursor was identified in the alpha-2 band of the proteome, leading to speculation 
that clusterin may have a role in canine lymphoma.44  In our study, the CLU protein was identified in all canine 
serum samples, using both western blot analysis and ELISA. Although there was marked variation in CLU levels 
between individuals, serum CLU in samples from dogs diagnosed with MLSA was consistently, significantly 
lower than that of a healthy control population.  
 
Multiple studies investigating CLU in human epithelial neoplasia,29,32–34,57 show positive cytoplasmic or nuclear 
staining via immunohistochemistry (IHC) and some indicate increased serum CLU.36–38 Positive CLU staining via 
IHC has also been identified in a high percentage of anaplastic large cell lymphoma.31,41–43 However positive 
IHC staining in other forms of T-cell lymphoma and B-cell lymphoma is less common.31,41,43 Saffer et al.31 
identified cytoplasmic CLU staining as positive in 35% of lymphoid neoplasia assessed; but only present in a 
small subset (12%) of diffuse large B cell lymphoma (DLBCL) cases. An unrelated in vitro study,58 also identified 
only a very low basal level of CLU via fluorescence microscopy and real-time PCR, in the Toledo DLBCL cell line 
compared to B lymphocytes from healthy human blood. While our current study population did not have 
histopathology diagnosis/classification, DLBCL is one of the most common lymphoma types seen in the canine 
population, accounting for up to 56% of MLSA diagnosis.1,59,60 Our study, identifying low CLU levels in MLSA 
serum, is consistent with human literature which reports low CLU levels in B cell lymphoma and T cell 
lymphoma, with the exception of anaplastic large cell lymphoma.31,41,43  
 
It has been shown in lab-based cell lines that doxorubicin treatment upregulates secretory clusterin 
isoforms.30,58 Despite the majority of our patients receiving doxorubicin as part of their chemotherapy protocol 
(week 4 of CHOP), this trend was not seen, and overall the median CLU level of dogs with MLSA in CR was still 
significantly lower than healthy controls. Our study showed no significant increase or decrease in serum CLU 
following chemotherapy. Individual serum CLU concentration following treatment was unpredictable; some 
dogs had increased clusterin concentrations, while others decreased or remained relatively static in remission. 
Similar variation in serum CLU has been reported in a small subset of human patients with Hodgkin’s 
lymphoma following treatment with chemotherapy.30 To see whether CLU expression would alter with 
induction of remission, due to reduced burden of disease, our study samples from patients in remission were 
taken 4-6 weeks following the start of treatment, to allow time for CR to occur. Regardless, there was no 
significant increase or decrease in serum CLU found. It is possible that the small numbers in the study made 
the differences between pre-treatment samples and those in CR difficult to identify, or it may be that a single 
doxorubicin treatment in vivo is insufficient to cause the same alterations seen in vitro.  From these 
preliminary findings it cannot be excluded that a relative change in individual CLU level could act as a marker 
for remission, relapse or response in canine lymphoma, following chemotherapy. Additional investigations, 
with larger numbers of patients and more statistical power may be of benefit to investigate this further.  
CLU has been implicated in a wide number of physiological and pathological processes, including 
tumourigenesis, regulation of cell death, and aging.24,28,53 In humans there is a relationship between CLU 
expression and age, with CLU expression increasing from gestation to adulthood,24,61,62 although significant 
individual variation exists. The CLU levels within our healthy control population did not vary significantly in 
relation to age, combining data from two ELISA plates, although this may in part be due to small sample size 
and overall narrow age range (1-7years). The possible impact of age on CLU levels prompted further evaluation 
in this study, using age matched MLSA and control samples. When cohorts were age matched there remained 
a highly significant difference in serum CLU levels, with serum CLU significantly lower in MLSA in comparison to 
controls.   
 
Our study had several limitations and as a result, was very preliminary in nature. The study was partly 
retrospective, relying on patient records and stored samples. Samples frequently lacked histological 
confirmation of diagnosis and lymphoma subclassification and were therefore a heterogeneous group. In 
addition, since most cases were diagnosed cytologically, many of the samples were genotyped as B or T cell by 
PARR alone, rather than immunophenotyped by IHC or flow cytometry, although additional clinical 
information such as hypercalcaemia and mediastinal mass supported a diagnosis of T cell in 5 cases. With the 
small numbers in our study, it was not possible to say if serum CLU varied between B and T cell cases. If any 
cases in sample group one had been immunophenotyped incorrectly by using PARR alone, it may have 
affected the comparison between untreated cases and those unrelated cases in remission, although 
comparisons between MLSA dogs and controls would be unaffected. While every precaution was taken to 
ensure the integrity of the cases and samples selected, the history of the freeze/thaw cycles during storage 
were not always known. Additional studies with larger cohorts would be beneficial to increase statistical 
power, especially due to the wide individual variation in CLU levels. In addition, further investigations 
particularly to evaluate cytoplasmic CLU expression in canine malignant lymphoma tissue, concurrently, via 
IHC, may help clarify the relationship between circulating levels and tumour progression.  
 
Conclusion 
Serum CLU is significantly lower in patients with MLSA, although substantial individual variation exists.  Results 
suggest that serum CLU may have limited benefit as a diagnostic biomarker, or marker of remission, although 
the potential prognostic value of CLU has not been investigated and would require more precise 
subclassification and immunophenotyping of samples. Additional studies with larger sample numbers are 
warranted, including further immunohistochemical evaluation of CLU in lymph nodes/tissue, to fully evaluate 
CLU expression in canine lymphoma.  
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Figure titles and legends 
 
Figure 1): A western blot analysis of serum CLU, in samples of varying protein concentrations. 
Confirming antibody specificity, showing the CLU protein at approx. 37kDa in the presence of the primary 
anticlusterin antibody but not with the secondary antibody only. 
The position of the molecular weight marker (Mk), annotated at 48 and 37kDa. 
 
Figure 2): Western blot analysis of serum CLU.  
 
i) Western blot of serum CLU in dogs with MLSA pre-treatment (n=12, A1-A12) and healthy controls 
(n=12, C1-C12).  
ii) Western blot of serum CLU in dogs with MLSA in CR (n=12, B1-B12) and healthy controls (n=12, 
C1-C12).  
iii) Western blot of serum CLU in dogs with MLSA pre-treatment (n=12, A1-A12) and unrelated dogs 
with MLSA in CR (n=12, B1-B12). 
 
Figure 3): Serum CLU levels, from western blot analysis, comparing dogs with MLSA pre-treatment, unrelated 
dogs with MLSA in CR and healthy controls. 
 
Vertical scatter graphs showing data distribution from each western blot: 
i) Comparing dogs with MLSA pre-treatment (A, n=12) with healthy controls (C, n=12). 
ii) Comparing dogs with MLSA in CR (B, n=12) and healthy controls (C, n=12). 
iii) Comparing dogs with MLSA pre-treatment (A, n=12) with unrelated dogs with MLSA in CR (B, 
n=12).  
Data presented with median and interquartile range.  
No significant difference in CLU between any of the three cohorts.  
 
Figure 4): Serum CLU concentrations, from ELISA analysis, comparing dogs with MLSA pre-treatment, 
unrelated dogs in CR and healthy controls.  
 
Vertical scatter graphs showing data distribution from ELISA: comparing dogs with MLSA pre-treatment (A, 
n=12), unrelated dogs with MLSA in CR (B, n=12) and healthy controls (C, n=12).  
Data presented with median and interquartile range.  
ANOVA revealed significant difference in CLU between the three cohorts. Serum CLU concentration was 
significantly higher in the controls in comparison to both MLSA pre-treatment and in CR (Bonferroni 
comparison p<0.05) There was no significant difference between dogs with MLSA prior to treatment and in CR.   
*** p<0.001 
* p<0.05 
 
Figure 5): Serum CLU concentrations, from ELISA analysis, comparing serum CLU in dogs with MLSA pre-
treatment (n=18), and at time of CR (n=18); paired samples from the same individuals.  
 
i) Vertical scatter graphs showing data distribution from each ELISA: comparing CLU in dogs with 
MLSA pre-treatment and at time of CR. Data presented with median and interquartile range. 
 
ii) Second line graph documenting no significant trend for changes in individual CLU concentration 
following treatment and achieving CR.   
 
Statistical analysis revealed no significant difference in individual serum CLU concentrations in dogs with MLSA 
following treatment.  
 
Figure 6): Serum CLU concentrations, from ELISA analysis, comparing dogs with MLSA pre-treatment (n=18) to 
healthy controls (n=18); age matched samples. 
 
Vertical scatter graphs showing data distribution from ELISA: comparing dogs with MLSA pre-treatment and 
healthy control dogs. Data presented with median and interquartile range.  
Statistical analysis revealed significant difference in CLU between the two cohorts, with serum CLU 
concentration significantly higher (p<0.05) in healthy controls in comparison to dogs with MLSA prior to 
treatment. 
*** p<0.001  
 
 
Table 1) Signalment of sample group one, consisting of dogs with MLSA pre-treatment (n=12, cohort A), 
unrelated dogs with MLSA in CR (n=12, cohort B) and healthy controls (n=12, cohort C).  
 
 Pre Treatment 
MLSA  
(A, n=12) 
CR 
MLSA 
(B, n=12) 
 
Control 
(C, n=12) 
 
p values 
Median Age (years) 
Range  
8  
5 - 12  
7.5 
4 - 12 
4 
1 - 7 
ANOVA 
p < 0.05 
Sex:  
Male entire 
Male neutered 
Female entire 
Female neutered 
 
4 
5 
3 
0 
 
3 
4 
0 
5 
 
3 
4 
1 
4 
 
Chi squared 
p > 0.05 
Stage: 
II 
III 
IV 
V 
 
0 
0 
4 
8 
 
1 
3 
6 
2 
 
N/a 
 
Chi squared 
p < 0.05 
Substage: 
a 
b 
 
3 
9 
 
5 
7 
 
N/a 
 
Fisher’s exact 
p > 0.05 
Immunophenotype: 
B 
T  
 
7 
1 
 
10 
0 
 
N/a 
 
Fisher’s exact 
p > 0.05 
Breed: 
Beagle  
Border collie 
Border terrier 
Boxer 
Cairn Terrier 
Cavalier King Charles spaniel 
Cocker spaniel 
Crossbreed 
Dachshund 
Doberman pinscher 
Flat coated retriever 
German shepherd 
Golden retriever 
Gordon setter  
Greyhound 
Hungarian vizsla  
Jack Russel terrier 
Labrador retriever 
Tibetan terrier 
Whippet 
 
0 
3 
1 
2 
1 
1 
0 
1 
0 
0 
0 
0 
0 
1 
0 
0 
0 
2 
0 
0 
 
1 
2 
0 
0 
0 
0 
1 
1 
1 
0 
0 
1 
1 
0 
0 
1 
1 
0 
1 
1 
 
0 
0 
0 
0 
0 
0 
0 
1 
0 
1 
1 
2 
3 
0 
1 
0 
0 
3 
0 
0 
 
- 
 
  
Table 2) Signalment of sample group two, consisting of dogs with MLSA pre-treatment (n=18), and at time of 
CR (n=18); paired samples from the same individuals.  
 
 Paired Samples  (n=18) 
 
Median Age (years) 
Range  
8.3 
5 - 14  
Sex:  
Male entire 
Male neutered 
Female entire 
Female neutered 
 
4 
5 
2 
7 
Stage: 
II 
III 
IV 
V 
 
0 
3 
9 
6 
Substage: 
a 
b 
 
11 
7 
Immunophenotype: 
B 
T  
 
10 
2 
Breed:  
Border collie 
Cocker spaniel 
Crossbreed 
German shepherd 
Golden retriever 
Jack Russel terrier 
Labrador retriever 
Parsons terrier 
Shih Tzu 
Spinoni  
Tibetan terrier 
West Highland White terrier  
Yorkshire terrier 
 
3 
1 
1 
1 
3 
1 
2 
1 
1 
1 
1 
1 
1 
 
 
  
Table 3) Signalment of sample group three, consisting of dogs with MLSA pre-treatment (n=18) and healthy 
controls (n=18); age matched sample cohorts. 
 
 Pre-treatment (n=18) 
 
Controls  (n=18) p values 
Median Age (years) 
Range  
6 
3 - 7 
5 
4 - 7 
Mann Whitney U Test 
p > 0.05 
Sex:  
Male entire 
Male neutered 
Female entire 
Female neutered 
 
4 
8 
1 
5 
 
4 
5 
1 
8 
 
Chi squared  
Fisher’s exact 
p > 0.05 
Stage: 
II 
III 
IV 
V 
 
0 
7 
8 
3 
 
N/a 
 
- 
Substage: 
a 
b 
 
7 
11 
 
N/a 
 
- 
Immunophenotype: 
B 
T  
 
5 
9 
 
N/a 
 
-  
Breed:  
Bernese Mountain dog 
Border collie 
Boxer 
Bullmastiff 
Cocker spaniel 
Crossbreed 
Doberman 
Dogue de Bordeaux 
Flat-coated retriever 
Golden retriever 
Greyhound 
Jack Russel terrier 
Labrador retriever 
Lurcher 
Shetland sheepdog 
Springer spaniel 
Tibetan terrier 
Weimeraner 
 
1 
3 
1 
1 
2 
1 
0 
1 
1 
3 
0 
1 
0 
1 
1 
0 
1 
0 
 
0 
0 
0 
0 
0 
1 
1 
0 
0 
2 
8 
0 
4 
0 
0 
1 
0 
1 
 
- 
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